AI Insight
This study investigates the molecular mechanism by which a potent antileishmanial compound achieves selective binding to AT-rich regions of DNA. The researchers determined that direct interactions between amidinium groups on the drug molecule and phosphate groups in the DNA backbone play a central role in guiding this AT-selective recognition. These structural and biochemical findings clarify how the compound distinguishes between AT and GC base pairs at the molecular level, advancing understanding of minor groove binding drugs.
Why it matters
Leishmaniasis is a neglected tropical disease affecting millions of people worldwide, and identifying the precise binding mechanism of effective antileishmanial compounds could inform the rational design of improved therapeutics with greater selectivity and reduced toxicity.